The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Viatris Inc. (VTRS) recently reported a fourth quarter that fell short of Wall Street expectations, missing revenue and earnings targets. The ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Coca-Cola ...

Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the U.S. Food and Drug Administration to take action against “bad actors” selling counterfeit weight loss drugs.

Weight loss jab use rising among people with eating disorders, experts warn as NHS chief calls for crackdown - Online ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.

Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...